Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 9/20 | 0.61 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.50 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13585407 | 1.00 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL4246388 | 1.00 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL12721121 | 0.94 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL13585203 | 0.94 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL13585205 | 0.94 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL12087460 | 0.93 | PTGFR (0.53) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL12640068 | 0.92 | PTGFR (0.72) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL5575169 | 0.92 | PTGFR (0.72) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL13585471 | 0.92 | ABCB11 (0.65) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL13585467 | 0.92 | ABCB11 (0.65) | PTGFRPTGER3ABCB11AKR1C3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2495235-B1 | Process for the synthesis of prostaglandins and intermediates thereof | NEWCHEM S P A (IT) | 2015-08-05 | — | — | EP | disclosed |
| US-8901319-B2 | Process for the preparation of F-series prostaglandins | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901319-B2 | Process for the preparation of F-series prostaglandins | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2014-12-02 | — | — | US | disclosed |
| US-8742143-B2 | Process for the preparation of prostaglandin analogues | SCINOPHARM TAIWAN, LTD. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-20130211128-A1 | Process for the Preparation of Prostaglandin Analogues | SCINOPHARM TAIWAN LTD. (TW) | 2013-08-15 | — | — | US | disclosed |
| US-8436194-B2 | Process for the preparation of prostaglandin analogues and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2013-05-07 | — | — | US | disclosed |
| US-20120283451-A1 | PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2012-11-08 | — | — | US | disclosed |
| US-20120283451-A1 | PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2012-11-08 | — | — | US | disclosed |
| WO-2011046569-A1 | PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS | CAYMAN CHEMICAL COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20090259058-A1 | Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof | SCINOPHARM TAIWAN LTD. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259058-A1 | Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof | PTGIS, PTGES, PTGER1 | PTGFR 13/4885PTGER3 15/4885ABCB11 2619/4885 |
| US-20120283451-A1 | PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS | PTGIS, PTGES, PTGFR | PTGFR 3/4885PTGER3 12/4885ABCB11 3306/4885 |
| US-20130211128-A1 | Process for the Preparation of Prostaglandin Analogues | PTGIS, PTGES, PTGER1 | PTGFR 14/4885PTGER3 11/4885ABCB11 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.